CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy sold 19,120 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $24.13, for a total transaction of $461,365.60. Following the completion of the transaction, the chief executive officer now owns 23,365 shares of the company’s stock, valued at $563,797.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) opened at 21.50 on Monday. The stock’s market capitalization is $792.64 million. CytomX Therapeutics, Inc. has a 52 week low of $9.85 and a 52 week high of $24.67. The company has a 50-day moving average of $17.37 and a 200-day moving average of $15.69.
CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.30). The firm had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. On average, analysts anticipate that CytomX Therapeutics, Inc. will post ($1.47) EPS for the current year.
A number of equities analysts have recently commented on CTMX shares. Bank of America Corporation raised their price objective on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. Nomura raised their price objective on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. Wedbush set a $37.00 price objective on shares of CytomX Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 4th. Cowen and Company reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday, August 8th. Finally, Jefferies Group LLC set a $25.00 target price on shares of CytomX Therapeutics and gave the company a “buy” rating in a research note on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $32.67.
Several hedge funds and other institutional investors have recently bought and sold shares of CTMX. Legal & General Group Plc boosted its position in shares of CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 1,434 shares during the last quarter. First Quadrant L P CA bought a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $160,000. Cubist Systematic Strategies LLC bought a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $174,000. Goldman Sachs Group Inc. bought a new position in shares of CytomX Therapeutics during the 1st quarter valued at approximately $190,000. Finally, Voya Investment Management LLC bought a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $203,000. Hedge funds and other institutional investors own 59.97% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.